Latest Product Development News

Page 2 of 109
Proteomics International has launched a discounted A$5 million share purchase plan as it moves from product development into commercial rollout. Eligible shareholders can buy shares at A$0.10 and may receive a free attaching option, subject to approval.
Ada Torres
Ada Torres
2 Nov 2026
Pathkey.AI has secured its first Chipforge customer contract ahead of the semiconductor platform’s commercial release, while a $2.8 million placement lifted quarter-end cash to $5.83 million. The company remains early-stage, with just $10,000 in customer receipts during the September quarter and further commercial conversion still to prove.
Sophie Babbage
Sophie Babbage
30 Oct 2026
Cadoux Limited (ASX:CCM) has strengthened the technical case for its high-purity alumina and rare earths portfolio, including battery qualification and new Danube mineralisation beyond its previous exploration envelope. The progress comes with a thinner cash buffer, no listed financing facilities and several commercial milestones still ahead.
Victor Sage
Victor Sage
30 Oct 2026
SportsHero says its rebuilt HeroPlay Gaming Universe is nearly ready for a November commercial launch after adding commerce, vouchers, payments and digital entertainment products. The expansion broadens the platform materially, but the next test is whether those capabilities translate into transaction revenue before cash burn becomes more pressing.
Victor Sage
Victor Sage
30 Oct 2026
FirstWave Cloud Technology delivered positive EBITDA in its first FY27 quarter, but cash fell to just A$83,000 before a post-quarter A$1.06 million placement restored near-term liquidity. The company is now balancing product launches and AI commercialisation against A$1.3 million of contract renewals due in December.
Victor Sage
Victor Sage
30 Oct 2026
BCAL Diagnostics has completed clinical validation for BREASTESTplus 2 across all breast densities and is targeting a November launch, while expanding Avantect Multicancer access. The commercial push comes alongside $1.895 million in quarterly operating cash outflows, only $580,000 in cash at quarter end and a growing strategic stake in Genetic Signatures.
Ada Torres
Ada Torres
30 Oct 2026
Mach7 Technologies has completed a costly FY26 reset, cutting operating expenditure by 16% while revenue fell 17% and the net loss widened to A$8.9 million. The company enters FY27 with a higher recurring-revenue mix, new customer orders and A$19.9 million in cash, but no earnings guidance and plenty to prove.
Victor Sage
Victor Sage
30 Oct 2026
Bio-Gene Technology has moved closer to two commercialisation milestones, with Qcide product work progressing in Japan and a first Flavocide regulatory submission targeted for Q2 2027. The company ended September with A$2.103 million in cash, equivalent to an estimated 2.18 quarters of funding at the quarter’s operating cash rate.
Victor Sage
Victor Sage
30 Oct 2026
Wrkr’s platform activity accelerated sharply in the first quarter of Payday Super, with contributing TFNs nearly tripling and estimated ARR reaching A$17 million. The next test is converting that adoption into transaction revenue while bringing cash costs down.
Victor Sage
Victor Sage
30 Oct 2026
Raiz Invest delivered solid Q1 FY27 growth, with funds under management rising 20.2% to $2.40 billion and customer numbers reaching 354,202. But the fintech still cannot reliably quantify the potential impact of historical tax matters now under expert and regulatory review.
Claire Turing
Claire Turing
30 Oct 2026
xReality Group expanded its Operator XR customer base, recurring revenue and sales pipeline in the first quarter, while securing its first US Marine Corps order after quarter end. But the company remains focused on completing its FY26 audit and reinstating trading, with $1.4 million in quarter-end cash against $4.55 million of secured debt.
Sophie Babbage
Sophie Babbage
30 Oct 2026
Novatti’s AU/NZ quarterly transaction value rose to $1.2 billion, but regulatory disruption to international BPAY payments pushed revenue lower and left Cash EBITDA negative. The company is targeting an early 2027 relaunch while relying on pipeline conversion and product mix improvements to support its next phase of growth.
Claire Turing
Claire Turing
30 Oct 2026

Browse the archive

Full archive